After confirmation of visceral leishmaniasis, the patients were treated with Abelcet
(amphotericin B lipid complex) (Teva Pharma BV, Harlow, UK) according to the manufacturer's guidelines.
Pharmacokinetic profile of ABELCET
(amphotericin B lipid complex injection): combined experience from phase I and phase II studies.
Originally owned by The Liposome Company in the mid-90s, the building was used for the initial scale-up and launch of Abelcet
. In 2010, the Sigma-Tau Group acquired the drug and facility.
Most of the currently available AmB nanoformulations are lipidbased (Ambisome, Amphocil, and Abelcet
) though some are also available in micellar (Fungizone) and nanosuspension form .
Liposomal Liposomal amphotericin B amphotericin B (abelcet
) 350 mg IV (abelcet
Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet
) in the prophylaxis of invasive fungal infections following lung transplantation.
The article includes a description of a recently reported mix-up between the lipid complex formulation amphotericin B (Abelcet
) and the conventional amphotericin B formulation (Fungizone), along with suggested strategies to prevent recurrence.
Warning: Prevent mix-ups between conventional amphotericin B (Fungizone) and lipid-based amphotericin B products (AmBisome or Abelcet
) [electronic version].
Confusion arose as the original "conventional" form, branded as Fungizone, has a dose of about 1mg per kg of a patient's weight, but modern forms, branded as Ambizone and Abelcet
, had dosages of 3mg and 5mg per kg.
The products sold include the cancer drug Oncaspar, fungal infection treatment Abelcet
, meningitis drug DepoCyt, and Adagen, which is used for severe combined immunodeficiency disease, or "Bubble Boy Disease." Enzon has said it will now focus on experimental cancer drugs and technologies.
Enzon's specialty pharmaceutical division covers the Oncaspar, Adagen, DepoCyt and Abelcet
marketed products and a manufacturing facility in Indianapolis, Indiana.
Biopharmaceutical company Enzon Pharmaceuticals Inc (Nasdaq:ENZN) reported on Friday the completion of the sale of its speciality pharmaceutical business for USD300m in cash subject to customary post-closing working capital adjustment to the sigma-tau Group.The speciality pharmaceutical business includes four marketed products, Oncaspar, Adagen, DepoCyt and Abelcet
, as well as the manufacturing facility in Indianapolis, Indiana.